US- DMF |
DRUGCOAT SERIES | MONOGRAPHS | PHYSICAL FORM | DISSOLUTION PROPERTIES |
| AQUEOUS ENTERIC COATING | ||||
| AVAILABLE | DRUGCOAT L30D | USP/NF: Methacrylic Acid And Ethyl Acrylate Copolymer Dispersion Ph. Eur.: Methacrylic Acid-Ethyl Acrylate Copolymer(1:1) Dispersion 30% |
Aqueous Dispersion 30% | Dissolve above pH 5.5 |
| DRUGCOAT L 100-55 | USP/NF: Methacrylic Acid And Ethyl Acrylate Copolymer Ph. Eur.: Methacrylic Acid- Ethyl Acrylate Copolymer (1:1) Type A |
Powder | ||
| DRUGCOAT L 100-55D | USP/NF: Partially–Neutralized Methacrylic Acid & Ethyl Acrylate Copolymer Ph. Eur.: Methacrylic Acid- Ethyl Acrylate Copolymer (1:1) Type B |
Powder | ||
| NON AQUEOUS ENTERIC COATING | ||||
| AVAILABLE | DRUGCOAT L 100 | USP/NF: Methacrylic Acid And Methyl Methacrylate Copolymer (1:1) Ph. Eur.: Methacrylic Acid – Methyl Methacrylate Copolymer (1:1) |
Powder | Dissolve above pH 6.0 |
| DRUGCOAT L 12.5 | Organic Solution 12.5% | |||
| COLON TARGETED ENTERIC COATING | ||||
| DRUGCOAT S 100 | USP/NF: Methacrylic Acid And Methyl Methacrylate Copolymer (1:2) Ph. Eur.: Methacrylic Acid – Methyl Methacrylate Copolymer (1:2) |
Powder | Dissolve above pH 7.0 | |
| DRUGCOAT S 12.5 | Organic Solution 12.5% |
Our company revolves around giving maximum to the two pillars that lay the foundation for our business: People and Product. Through constant R&D and innovation, the company plans to build a better future without compromising the quality and safety to reach a higher level of excellence in healthcare facilities.
Let’s create opportunities together